- Rekrutierung läuft
Double-blind, randomised, placebo-controlled, phase IIb trial on the efficacy and safety of norursodeoxycholic acid tablets in patients with non-alcoholic steatohepatitis (NASH)
- Rekrutierung läuftMRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapse TUD-PEMAZA-068IndikationenMolekulare Marker
- Rekrutierung läuftA Phase 2, single arm study on dacarbazine (DTIC) followed by immunotherapy re-challenge in unresectable or metastatic melanoma with primary resistance to PD-1/PD-L1 or PD-1 + CTLA4 BlockadeIndikationen
- Rekrutierung läuftEfficacy Comparison of Dostarlimab Plus Chemotherapy vs Pembrolizumab plus Chemotherapy in Participants with metatstatic non-squamous non-small Cell Lung
- Rekrutierung läuft
An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphom
Molekulare Marker - Rekrutierung läuft
Radiochemotherapie +/- Durvalumab zur Behandlung des lokal fortgeschrittenen Analkarzinoms. Eine multizentrische, randomisierte Phase II-Studie der German Anal Cancer Study Group
Molekulare Marker - Rekrutierung läuftRIST-rPB-2015-P Prospective Pilot Trial to assess a multimodal targeted therapy in children, adolescent and young adults with relapsed or refractory high-grade pineoblastoma
- Rekrutierung läuftA Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRASG12C Mutation After Failure of Prior Standard Therapies
- Rekrutierung läuftCMV in allogeneic hematopoietic stem cell transplant patients
- Rekrutierung läuft
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a
Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory
Multiple Myeloma.Phase 2 (Part 3)
Molekulare Marker